Section 3 of the Indian Patent Act, 1970 – Overview

Section 3 of the Patent Act specifies inventions that are not patentable in India. These exclusions aim to balance innovation with public interest, morality, and access to essential knowledge.

Key Provisions:

Section 3(a): Frivolous or contrary to natural laws (e.g., perpetual motion machines).

Section 3(b): Inventions contrary to public order, morality, or life, health, or environment.

Section 3(c): Mere discovery of scientific principle or abstract theory.

Section 3(d): Mere discovery of a new form of a known substance without increased efficacy.

Section 3(e-f): Mere methods of agriculture, horticulture, business, or mathematical algorithms.

Section 3(g-i): Certain biological processes, plants, and animals (except microorganisms).

Section 3(k): Traditional knowledge or naturally occurring substances.

Landmark Case Laws on Section 3 Exclusions

1. Novartis AG v. Union of India & Others (2013) – Supreme Court of India

Facts:
Novartis sought a patent in India for Glivec (imatinib mesylate), a cancer drug, claiming it was a new form of a known substance.

Issues:

Whether the new crystalline form of an existing molecule qualifies as a patentable invention.

Application of Section 3(d) – efficacy requirement.

Judgment:
The Supreme Court rejected Novartis’ patent application, holding that:

Mere incremental modification of a known drug is not patentable unless it shows enhanced efficacy.

Section 3(d) prevents evergreening of pharmaceutical patents.

Outcome:
Novartis’ application was denied. India’s patent law prioritizes access to medicines and public health over minor modifications.

Significance:

Reinforces Section 3(d) as a check against trivial pharmaceutical patents.

2. Syngenta Participations AG v. Controller of Patents (2011) – Delhi High Court

Facts:
Syngenta applied for a patent on a new formulation of pesticide. The Controller rejected the patent under Section 3(d) for being a mere new form of a known chemical without enhanced efficacy.

Issues:

Whether formulation improvements without significant efficacy gain are patentable.

Judgment:
Court upheld the Controller’s rejection, holding that Section 3(d) requires substantive technological advancement, not cosmetic changes.

Outcome:
Patent denied.

Significance:
Strengthens the principle that minor modifications of existing substances are not patentable in India.

3. Monsanto Technology LLC v. Nuziveedu Seeds Ltd. (2014) – Delhi High Court

Facts:
Monsanto claimed patents on genetically modified cotton seeds. Indian farmers and local companies argued these were biological processes excluded under Section 3(h).

Issues:

Are seeds or plants patentable under Indian law?

Section 3(h) excludes plants and essentially biological processes.

Judgment:
Court held that patents on seeds and natural plants are not allowed; only microorganisms and technical processes are patentable.

Outcome:
Claims for patenting GM cotton seeds were partially rejected.

Significance:
Confirms Section 3(h) protects farmers’ rights and biodiversity.

4. Controller of Patents v. F. Hoffmann-La Roche Ltd. (2009)

Facts:
Roche filed a patent application for a new dosage form of a known anti-cancer drug. The Controller rejected it citing Section 3(d).

Issues:

Does a new dosage form qualify as a patentable invention?

Judgment:
Controller’s rejection was upheld. Section 3(d) applies to new forms of known substances lacking efficacy improvement.

Outcome:
Patent was denied.

Significance:
Reinforces anti-evergreening provisions in Indian patent law.

5. Monsanto v. UOI – Supreme Court (2016)

Facts:
Monsanto challenged Section 3(h) exclusions for plants and seeds while claiming a patent on hybrid cotton.

Issues:

Whether genetically modified plants can be patented.

Judgment:
Supreme Court reaffirmed that plants, seeds, and biological processes are excluded from patentability, unless the invention is a technical process applied to microorganisms.

Outcome:
Patent claims on seeds and plants were rejected.

Significance:
Protects traditional agriculture and biodiversity from monopolization.

6. Novartis v. Controller of Patents – Glivec Case (Expanded)

Facts:
The patent application claimed a beta crystalline form of imatinib mesylate.

Issues:

Whether improved bioavailability alone satisfies Section 3(d).

Judgment:
SC clarified that improved bioavailability is not enough; efficacy must be therapeutically significant.

Outcome:
Patent refused.

Significance:
Guideline for pharma: innovative medicines must show real therapeutic improvement.

7. Cipla Ltd. v. Bayer Corporation (2007) – Delhi High Court

Facts:
Cipla argued against Bayer’s patent for a drug, claiming lack of novelty and exclusion under Section 3(c).

Issues:

Mere discovery of a new use for a known substance – patentable?

Judgment:
Court held that discovering a new use of a known substance is not patentable; Section 3(c) excludes scientific principles and abstract ideas.

Outcome:
Patent claim rejected.

Significance:
Clarifies that new uses of existing chemicals must meet inventive step and not merely be a discovery.

Key Takeaways – Section 3 Exclusions

Section 3(d): Prevents evergreening by requiring enhanced efficacy.

Section 3(h): Protects plants, seeds, and essentially biological processes.

Section 3(c): Excludes abstract principles or mere discoveries.

Public Interest: Exclusions protect public health, farmers, and biodiversity.

Patent Enforcement: Minor modifications or dosage/form changes are not patentable unless they offer significant technical improvement.

Judicial Principle: Courts consistently balance innovation incentives with societal and public interest.